Eupraxia Pharmaceuticals Inc
TSX:EPRX

Watchlist Manager
Eupraxia Pharmaceuticals Inc Logo
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Watchlist
Price: 8.57 CAD 1.06% Market Closed
Market Cap: 434.1m CAD

Eupraxia Pharmaceuticals Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Eupraxia Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Eupraxia Pharmaceuticals Inc
TSX:EPRX
Cash from Operating Activities
-CA$30m
CAGR 3-Years
-27%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Cash from Operating Activities
$7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Cash from Operating Activities
-$70.1m
CAGR 3-Years
N/A
CAGR 5-Years
-95%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cash from Operating Activities
$120.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Cash from Operating Activities
-$252m
CAGR 3-Years
-43%
CAGR 5-Years
-75%
CAGR 10-Years
-32%
Spectral Medical Inc
TSX:EDT
Cash from Operating Activities
-CA$9.1m
CAGR 3-Years
2%
CAGR 5-Years
-115%
CAGR 10-Years
0%
No Stocks Found

Eupraxia Pharmaceuticals Inc
Glance View

Market Cap
433.6m CAD
Industry
Biotechnology

Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.

EPRX Intrinsic Value
Not Available

See Also

What is Eupraxia Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-30m CAD

Based on the financial report for Dec 31, 2024, Eupraxia Pharmaceuticals Inc's Cash from Operating Activities amounts to -30m CAD.

What is Eupraxia Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-42%

Over the last year, the Cash from Operating Activities growth was -45%. The average annual Cash from Operating Activities growth rates for Eupraxia Pharmaceuticals Inc have been -27% over the past three years , -42% over the past five years .

Back to Top